Ye Weiguo 4

What Happened
Ye Weiguo, Chief Operating Officer of Gyre Therapeutics (GYRE), exercised a total of 20,918 stock options (code M) at an exercise price of $0.75 per share and sold the resulting shares in open-market transactions (code S). On June 9, he exercised 14,500 options (cost $10,875) and sold those shares for $89,030 (weighted avg $6.14; sales ranged $6.0597–$6.19). On June 10, he exercised 6,418 options (cost $4,814) and sold those shares for $39,856 (weighted avg $6.21; sales ranged $6.11–$6.30). The combined proceeds from the sales were about $128,886 while the total exercise cost was about $15,689.

Key Details

• Transaction dates: June 9, 2026 (14,500 shares) and June 10, 2026 (6,418 shares).
• Exercise price paid: $0.75 per share (total paid ≈ $15,689).
• Sale proceeds (weighted averages reported): $89,030 (June 9, avg $6.14; range $6.0597–$6.19) and $39,856 (June 10, avg $6.21; range $6.11–$6.30). Combined proceeds ≈ $128,886.
• The filing includes separate entries showing the derivative (option) disposition at $0.00 — reflecting the conversion/exercise of the options.
• Footnote F3: the options were fully vested. Footnotes F1/F2: weighted-average sale prices reported; SEC staff can request the exact breakdown by price.
• Shares owned after the transactions: not specified in the information provided.
• Filing date: June 11, 2026 — appears timely (Form 4 is generally due within two business days).

Context

• Because the exercised shares were sold the same days they were exercised, this effectively results in immediate sale of shares received from option exercise (often described as a cashless exercise or immediate disposition).
• These are executive transactions (COO) and are reported disclosures of option exercise followed by open-market sales; they are factual records of insider activity and do not, by themselves, indicate the insider’s future view of the company.